Description and Brand Names
Drug information provided by: IBM Micromedex
US Brand Name
- Idhifa
Descriptions
Enasidenib is used to treat acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation in patients who have not responded to other treatments or to those whose cancer has come back after treatment.
Enasidenib is an isocitrate dehydrogenase-2 inhibitor. It works by blocking the enzyme isocitrate dehydrogenase which is needed by the cancer cells to grow.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: Feb. 01, 2022
Copyright © 2022 IBM Watson Health. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.